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Blood platelets play important roles during pathological thrombocytopenia in
streptococcal toxic shock syndrome (STSS). Streptococcus suis (S. suis) an emerging
human pathogen, can cause STSS similarly to S. pyogenes. However, S. suis
interactions with platelets are poorly understood. Here, we found that suilysin (SLY),
different from other bacterial cholesterol-dependent cytolysins (CDCs), was the sole
stimulus that induced platelet aggregation. Furthermore, the inside-out activation of
GPIIb/IIIa of platelets mediated SLY-induced platelet aggregation. This process was
triggered by Ca2+ influx that depend on the pore forming on platelets by SLY.
Additionally, although SLY induced α-granule release occurred via the MLCK-dependent
pathway, PLC-β-IP3/DAG-MLCK and Rho-ROCK-MLCK signaling were not involved in
SLY-induced platelet aggregation. Interestingly, the pore dependent Ca2+ influx was also
found to participate in the induction of platelet aggregation with pneumolysin (PLY) and
streptolysin O (SLO), two other CDCs. It is possible that the CDC-mediated platelet
aggregation we observed in S. suis is a similar response mechanism to that used by a
wide range of bacteria. These findings might lead to the discovery of potential therapeutic
targets for S. suis-associated STSS.
Keywords: Streptococcus suis (S. suis), suilysin (SLY), platelet aggregation, Ca2+ influx, streptococcal toxic shock
syndrome (STSS)
INTRODUCTION
Streptococcal toxic shock syndrome (STSS) is a severe, invasive streptococcal infection associated
with the sudden onset of shock, acute respiratory distress syndrome, renal failure, bacteremia,
and disseminated intravascular coagulation (DIC). The Gram-positive bacterium Streptococcus suis
serotype 2 (S. suis 2) is an emerging human pathogen. As well as causing disease in pigs, S. suis 2 can
also cause serious enzootic infections in humans, which are associated with septicemia, meningitis,
and endocarditis (Tang et al., 2006; Wangkaew et al., 2006). In 2005, China reported over 200
human cases of STSS that had an unusual clinical disease presentation and a mortality rate of up to
20% (Sriskandan and Slater, 2006). Thrombocytopenia and multisystem dysfunction, such as liver
failure, heart failure, and disseminated intravascular coagulation (DIC were found in more than
half of the STSS patients. Moreover, purpura and gangrenous changes are found to be the typical
skin manifestations in STSS patients (Tang et al., 2006; Yu et al., 2006).
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Platelet–bacterium interactions are known to be involved
in bacterial-associated diseases, such as infective endocarditis
(IE), DIC, and purpura gangrenosa. Lactococcus lactis that
expresses either ClfA or FnbpA was shown to be 100 times
more infective than the wild-type L. lactis strain in an animal
model of IE (Que et al., 2001). Helicobacter pylori infections
cause platelet activation in patients (Davi et al., 2005), and
P-selectin-dependent platelet aggregation might contribute to
H. pylori-associated thrombocytopenia in patients (Yeh et al.,
2010). Mouse infection models suggest that S. pneumoniae-
induced thrombocytopenia and DIC are caused by this
bacterium’s neuraminidase, which removes sialic acid from
platelet proteins and is involved in platelet clearance from
the circulation (Grewal et al., 2008). However, the interactions
between platelets and S. suis and the underlying molecular
mechanism(s) involved in these interactions remain poorly
understood.
Bacteria interact with platelets through a variety of
mechanisms (Cox et al., 2011). Previous studies have shown that
bacteria interact with platelets by direct binding to adhesion
factors such as GPIIb/IIIa (Miajlovic et al., 2010), GPIbα
(Plummer et al., 2005), and Toll-like receptor 4 (TLR4) (Stahl
et al., 2006), or by indirect binding to these adhesion factors
via plasma proteins such as fibrinogen (Walsh et al., 2008),
IgG (Fitzgerald et al., 2006), von Willebrand factor (O’seaghdha
et al., 2006), or complement 1q (Ford et al., 1996). In addition,
bacteria secrete toxins that activate platelets and cause platelet
aggregation (Lourbakos et al., 2001). However, our knowledge
of the molecular events by which bacterial toxins control
platelet–bacteria interactions is rudimentary.
Suilysin (SLY) is a 497 amino-acid protein belonging to the
cholesterol-dependent cytolysin (CDC) family, which has more
than 20 members, including pneumolysin (PLY) and streptolysin
O (SLO), which are expressed by S. pneumoniae and S. pyogenes,
respectively. Like other CDC family members produced by
Gram-positive bacteria, a classical feature of these toxins is their
ability to create transmembrane pores in cholesterol-containing
membranes, thereby causing cell lysis (Giddings et al., 2004;
Xu et al., 2010). In this study, different from other bacterial
cholesterol-dependent cytolysins (CDCs), we found that SLY
was the sole stimulus responsible for platelet activation and
aggregation induced by S. suis. We also found that the SLY-
induced pore dependent Ca2+ influx triggered “inside-out”
signaling to activate GPIIb/IIIa, which mediated SLY-induced
platelet aggregation. Our findings extend the similar observations
related to PLY- and SLO-induced platelet aggregation, which is
triggered by pore dependent Ca2+ influx.
EXPERIMENTAL PROCEDURE
Ethics Statement
The healthy donors who supplied blood for this study provided
written informed consent in accordance with the Declaration
of Helsinki. Approval was obtained from the Institutional
Medical Ethics Committee of the Academy of Military Medical
Sciences. This research was approved by Ethics Committee on
Animal Experimentation of the Chinese Association for the
Accreditation of Laboratory Animals Care (CAALAC), and it
included the relevant local animal welfare bodies in China. The
permit number for all the animal work [SCXK-(JUN) 2013-018]
was obtained from the Institutional Medical Ethics Committee
of the Academy of Military Medical Sciences, China. All efforts
were made to minimize suffering in the animals employed in this
study.
Reagents
Monoclonal mouse anti-human antibodies, including fluorescein
isothiocyanate (FITC) conjugated anti-CD42b (clone HIP1),
FITC conjugated anti-CD41a (clone HIP8), and the isotype
control antibodies were from BD Bioscience (USA). FITC
conjugated mouse anti-fibrinogen antibody was from Abcam
(USA). U73122, ML-7, Y27632, and eptifibatide acetate, which
are inhibitors for phospholipase C (PLC), myosin light chain
kinase (MLCK), rho-associated, coiled-coil-containing protein
kinase (ROCK), and CD41a, respectively, were from Sigma
Aldrich (USA). Cholesterol and EGTA were also purchased from
Sigma Aldrich. Adenosine diphosphate (ADP) was from MP
Biomedicals (USA). Quest Fluo-8 calcium fluorescence probe
was from AAT Bioquest R©, Inc. (USA). Wright’s stain was from
Beijing CellChip Biotechnology Co., Ltd., China.
Strains and Culture Supernatant
Chinese virulent S. suis strains (05ZYH33 and 4) were isolated
originally from an STSS patient (Pian et al., 2012). The sly
or mrp isogenic mutants of 05ZYH33 (1sly and 1mrp) were
constructed in our previous studies (He et al., 2014; Pian et al.,
2015). The 1mrp mutant was used as an irrelevant control
for 1sly in this study. The Canadian avirulent strain 1330,
which does not express SLY, was donated by Prof. Marcelo
Gottschalk (Université de Montréal, Montreal Quebec, Canada).
The European SLY+-associated virulent strains (4005 and s735)
were donated by Dr. Henk J. Wisselink. Group A streptococcus
(GAS) was the M1 type, E477. The above-mentioned bacterial
strains were stored in our laboratory. S. suis strains were cultured
in Todd-Hewitt broth (THB, BD Biosciences) at 37◦C for 4 h
(OD600 = 0.4, exponential growth phase) or 6 h (OD600 =
1.0, stationary growth phase) and then harvested for the next
experiments. Bacterial culture supernatants were obtained by
centrifugation of the cultures at 8000 rpm for 5 min, after
which they was filtered through a 0.22µm bacterial filter. The
filtered supernatants were stored in −80◦C for future use. In the
experiment where bacterial cells were used as the stimulus, S.
suis strains and GAS were washed three times with phosphate-
buffered saline (PBS) by centrifugation at 8000 rpm for 5 min and
were then re-suspended in PBS at a density of 2 × 109 CFU/ml
for use. Strains are listed in Table S1.
Preparation of Recombinant Suilysin
(rSLY), Pneumolysin (rPLY), Streptolysin O
(rSLO), and Factor H-Binding Protein (rFhb)
To express recombinant proteins rPLY and rSLO in E. coli,
the ORFs encoding PLY and SLO proteins (removed the signal
sequence) were amplified by PCR and were cloned into the
expression vector pTrcHis and transformed into E. coli strain
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BL21(DE3). The cloned gene sequences were confirmed by DNA
sequencing. For protein expression, E. coli were cultured in 1 l
of LB media containing 50µg/ml of ampicillin at 37◦C until the
culture reached mid-log growth phase (OD600 = 0.6–0.8), after
which 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was
added to the culture to induce expression of the recombinant
protein. Subsequently, the bacteria were cultured continuously
at 16◦C overnight. The bacterial culture was then collected by
centrifugation (HITICH, Japan) at 8000 rpm for 10 min and
the cell pellet was sonicated for 30 min on ice to release the
recombinant protein. Recombinant proteins were purified using
Ni2+ affinity chromatography columns (GE Healthcare). The
recombinant proteins rSLY (Lv et al., 2011) and the irrelevant
control protein rFhb (Pian et al., 2012) used in this study were
purified as reported previously. The bacterial strains, primers,
and plasmids used in this study are listed in Table S1.
Human Platelets
Whole blood from the healthy donors, who had not used anti-
platelet drugs within the previous 15 days, was withdrawn at
the 307 Hospital, and the blood from each person was collected
in a tube containing sodium citrate (final concentration, 3.2%)
(Shannon et al., 2007). A total of 6 ml of whole blood was
centrifuged at 900 rpm for 10 min in a horizontal centrifuge
(Sigma Aldrich) to prepare platelet-rich plasma (PRP, 3×108/ml).
The platelets in the PRP were marked by FITC conjugated anti-
CD41a (clone HIP8) and the purity was determined by flow
cytometry analysis. Whole blood was recentrifuged at 3000 rpm
for 5 min to obtain platelet-poor plasma (PPP), which was used
as a control for the aggregation assays.
Platelet Aggregation in PRP
Before the platelet aggregation detection assay was performed,
the purity of the platelets in the PRP was analyzed by flow
cytometry. Contaminating leukocytes were not seen in the PRP
isolated, and the purity of the platelets in the PRP was >99%
(Figure S1). Platelet aggregation was determined in a 4-channel
platelet aggregometer SE-2000 (Succeeder, China) as described
previously (Keane et al., 2010). Aggregation is represented by
changes in light transmission, and the light transmission of PPP
was used as the baseline. PRP (270µl) was added to a glass
cuvette and incubated at 37◦C for 1 min, and then one or other
of 30µl of SLY (final concentration was 1µg/ml), S. suis cells
(2×108 CFU/ml), 05ZYH33 supernatant (Sup), 1sly Sup, ADP
(20µM, as positive control), or PBS/THB (negative control)
was added to the cuvette. The rSLY (1µg/ml) possesses equal
hemolytic activity to the 05ZYH33 supernatant (10%) used in
this study (Figure 3A). However, The final concentration of SLY
in 05ZYH33 supernatant, as deduced from our previous study
(He et al., 2014), was≈0.15µg/ml. This might be due to the rSLY
used in this study was not added β-ME to keep its high hemolytic
activity for avoiding the negative effects of β-ME on platelets.
Hemolytic activity detecting assay was performed as reported
previously (Hao et al., 2013). The cuvettes were incubated at
37◦C for 10 min. To block platelet aggregation stimulation, PRP
(270µl) was pre-incubated with 2.7µl of EGTA (3mM), U73122
(20µM), eptifibatide (10µM), or anti-CD62P antibody (15µl)
at 37◦C for 10 min, or with 2.7µl ML-7 (100µM), or Y27632
(100µM) for 60 min before being exposed to the stimulus. To
test the effect of cholesterol, SLY (990 µl) was pre-incubated
with of 10µl cholesterol (100µg/ml) at 37◦C for 10 min before
addition to the platelets. Data are expressed as the mean ± SD.
The experiment was repeated three times independently, and
blood from a different donor was used in each experiment.
Observation of Platelet Aggregation in
Whole Blood by Microscopy
Whole blood (100µl) was incubated with 10 µl of SLY (1µg/ml)
or other stimuli at 37◦C for 10 min after which 5µl of the blood
sample was used to prepare a blood smear on a glass slide. After
the blood smear had dried completely, Wright’s stain was added
to cover the blood smear and an equal volume of PBS (pH 6.4–
6.8) was added 1 min later. Wright’s stain and PBS were gently
mixed and the blood smear was incubated with the mixture for
5 min. The slide was then washed gently with distilled water
and subjected to microscopic analysis using an oil-immersion
objective (Olympus, Japan).
Measurement of Platelet Lactic
Dehydrogenase (LDH) Release
LDH release was measured to evaluate the cytotoxicity of
recombinant SLY, PLY, and SLO to platelets. PRP was incubated
with the either one of the recombinant proteins and the
supernatant was collected by centrifugation at 3000 rpm for
5 min. LDH in the supernatant was measured by a CytoTox
96 R© Non-Radioactive Cytotoxicity Assay (Promega, USA). Cell
lysis buffer and PBS were used as the positive and the negative
controls, respectively. The relative cytotoxicity (%) = [(OD490
sample − OD490 PBS) ÷ (OD490 positive control − OD490
PBS)] × 100%. Data are expressed as the mean ± SD of three
independent experiments, with each experiment using blood
from a different donor.
Flow Cytometry Analysis of Platelet
Activation
The surface GPIIb/IIIa was detected by Flow cytometry with
FITC conjugated anti-CD41a (CD41a often referring to GPIIb,
clone HIP8), as per a previous description (Parimon et al.,
2013). Briefly, 100µl of heparinized human blood was incubated
with 15µl of FITC conjugated anti-human CD41a at 37◦C for
10 min. Next, rSLY or a different stimulus was added and
the blood was incubated for another 15 min. One mL of red
cell lysis buffer containing formalin was then added to the
blood to lyse the red cells and to fix the platelets at room
temperature for 8 min. After complete lysis of the red blood
cells, the blood was centrifuged and the cell pellet was washed
with PBS. The cell pellet was re-suspended in 300µl of PBS
and analyzed on an Accuri C6 flow cytometer (BD Biosciences,
USA). The surface CD41a was determined by measuring the
mean fluorescence intensity (MFI) of 10,000 events for each
sample. To test the effect of cholesterol, SLY was pre-incubated
with cholesterol (100µg/ml) for 10 min and the blood was
incubated with the mixture. To test the effect of EGTA, blood
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was pre-incubated with EGTA (3mM) for 10 min and then
incubated with rSLY or other stimuli. Fg binding to platelets was
also analyzed by flow cytometry. Briefly, 100µl of whole blood
was incubated with 1µl of FITC-conjugated anti-fibrinogen
polyclonal antibody at 37◦C for 10 min. The blood sample was
then analyzed by flow cytometry. Representative histograms of
the MFI for CD41a and fibrinogen binding are displayed. Data
are expressed as the mean MFI ± SD of three independent
experiments, with each experiment using blood from a different
donor.
Measurement of Dense Granule (or ATP)
Secretion
ATP secretion was determined to evaluate platelet activation after
stimulation (Arman et al., 2014). Briefly, 270µl of PRP was
incubated with 30µl of rSLY or 05ZYH33 supernatant or other
stimuli at 37◦C for 10 min. The supernatant was obtained by
centrifugation at 5000 rpm for 5 min. ATP in the supernatant
was measured using a luciferin-luciferase kit (CellTiter-Glo R© 2.0
Assay, Promega, USA), according to the manufacturer’s manual.
Data are expressed as the mean ± SD. The experiment was
repeated three times and blood from a different donor was used
in each experiment.
Calcium Influx to Platelets
A total of 200µl of PRP was added to each well of a 96-well
microplate. The plate was centrifuged at 2000 rpm for 10 min
and then washed twice with PBS. Next, 100µl of calcium probe
fluo-8 (5µM) was added to the wells and the plate was incubated
at 37◦C for 30 min. The plate was centrifuged at 2000 rpm for
10 min and then washed twice with 200µl of PBS to remove
any calcium probe remaining in the solution. The platelets were
re-suspended in 180µl of HBSS (containing 2mM Ca2+) or
D-HBSS (without Ca2+), and then either 20µl rSLY (1µg/ml),
rSLY (0.1µg/ml), rSLYP353V (1µg/ml), cholesterol (100µg/ml),
or other control reagents were added. Ca2+ influx to the platelets
was measured in a Varioskan Flash Multiplate Reader (Thermo,
USA).
In vivo Infection
05ZYH33 and mutant1sly were cultured at 37◦C in 5% CO2 for
about 6 h to stationary phase (OD600 = 1.0, ∼1×109 CFU/ml)
and then centrifuged at 8000 rpm for 5 min. PBS was used to
wash the bacteria and the dose was adjusted to∼1×109 CFU/ml.
Female BALB/c mice (6–8 weeks old) were challenged with
100µl (∼1×108 CFU) of 05ZYH33 or the mutant 1sly bacteria
through the caudal vein. Pathological changes were observed
by hematoxylin and eosin (H&E) pathological staining for 48 h
post-inoculation.
Statistical Analysis
Unless otherwise specified, all data are expressed as the mean ±
standard deviation. All the platelet aggregation test assays were
performed in PRP/human blood from three individual donors
in independent experiments. Differences between two groups
were assessed using an unpaired two-tailed Student’s t-test where
Levene’s-test did not show statistical significance (P > 0.05);
otherwise, non-parametric tests were used. For all tests, a value
of P < 0.05 was considered as the threshold for significance. All
statistical analyses were carried out using SPSS 15.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
SLY Is the Sole Stimulus Responsible for
Platelet Aggregation Induced by S. suis
To elucidate the biological basis for stimulus-induced platelet
aggregation, bacterial cells and stationary phase culture
supernatants from S. suis strains were tested for platelet
aggregation in human PRP. The 05ZYH33 stationary phase
(OD600 = 1.0) supernatant significantly induced platelet
aggregation, whereas the bacterial supernatant at exponential
growth phase (OD600 = 0.4) and 05ZYH33 bacterial cells did
not (Figures 1A,B), suggesting that there are secreted stimuli
that induce platelet aggregation. SLY is an important secreted
toxin of S. suis and high levels of it are produced at the end of
the exponential growth phase (Gottschalk et al., 1995); therefore,
we used it to test the aggregation-inducing activity of platelets.
Interestingly, different from other bacteria, SLY seemed to be the
sole stimulus responsible for platelet aggregation induced by S.
suis. Because neither1sly bacterial cells nor the supernatant were
able to induce platelet aggregation (Figures 1A,B). Moreover,
the supernatant from the SLY-negative Canadian strain 1330
culture and the heat-inactivated 05ZYH33 supernatant also
failed to induce platelet aggregation (Figure 1A). Additionally,
recombinant SLY (rSLY) stimulated platelet aggregation, whereas
the non-hemolytic recombinant mutant SLYP353V (rSLYP353V)
and the irrelevant control protein rFhb did not (Figure 1A).
Obvious platelet aggregation in the presence of the 05ZYH33
supernatant and rSLY was observed in aggregometer cuvettes
(Figure 1C), and was also evident on blood smears with
Wright’s stain (Figure 1D). In SLY+ S. suis-associated Chinese
and European strains, S. suis 1940 displayed poor hemolytic
activity (He et al., 2014). Interestingly, besides S. suis 1940, the
stationary phase (OD600 = 1.0) from other SLY+ S. suis strains
significantly induced platelet aggregation, whereas the bacterial
cells failed (Figure S2). Taken together, these results indicate
that SLY is the sole protein involved in S. suis-induced platelet
aggregation.
SLY Induced Platelet Aggregation
Occurred Via GPIIb/IIIa
During platelet activation, the agonist induces a change in platelet
shape, granular secretion, and inside–out signaling resulting
in a conformational change in the extracellular domains of
GPIIb/IIIa, thus allowing fibrinogen binding, while “outside-
in” signaling is activated and regulates the extent of platelet
aggregation (Zarbock et al., 2007).
ATP exists in dense granules and is often used as a measure
of dense granule release. Under resting conditions, platelets
do not release ATP from their dense granules. 05ZYH33
supernatant, rSLY protein, or positive control ADP significantly
stimulated ATP release from platelets (Figure 2A). GPIIb/IIIa
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FIGURE 1 | SLY is the sole stimulus of S. suis-induced platelet aggregation. (A) The culture supernatant of S. suis and recombinant proteins or (B) the washed
bacteria cells were added to PRP in a stirred cuvette. Platelet aggregation was expressed as a final percentage of light transmission detected by Platelet
Aggregometer se-2000. ADP (20µM) and GAS bacterial cells were used as the positive controls. Unpaired two-tailed Student’s t-tests were used and the threshold
for significance was P< 0.05; ns, not significant. Data are expressed as the mean ± SD of three independent experiments, with each experiment using blood from a
different donor. (C) Platelet aggregations were observed when detecting the light transmission of PRP stimulated by bacterial supernatant (at OD600 = 1.0) or rSLY.
(D) Wright’s staining of cytospin preparations of S. suis culture supernatant or rSLY protein-treated whole blood samples. 05ZYH33, wild type strain; 1sly, isogenic
mutant of sly; 1mrp, isogenic mutant of mrp (which was used as an irrelevant control for 1sly); 1330, SLY-negative Canadian strain; H-05ZYH33, heat-inactive
05ZYH33; Sup, supernatant; rSLY, recombinant SLY; rSLYP353V, recombinant non-hemolytic mutant of SLYP353V; rFhb, recombinant Factor H-binding protein, which
was used as an irrelevant protein and was purified by the same procedure as that used for rSLY.
is the most abundant platelet surface membrane glycoprotein
(∼70%), but there are additional pools of GPIIb/IIIa (∼30%)
in α-granule membranes (Phillips et al., 1988; Bennett,
2005), and the increased surface GPIIb/IIIa from the secreted
contents of α-granules (when platelets activating) has also been
detected by FITC conjugated anti-CD41a (GPIIb). Similarly
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FIGURE 2 | Platelet activation by SLY, and GPIIb/IIIa (CD41a) mediated the SLY-induced platelet aggregation. (A) SLY induces dense granule release from
platelets. PRP was incubated with S. suis culture supernatant or SLY protein (1µg/ml). The Mann–Whitney U-test was used for statistical analysis. (B,C) S. suis
culture supernatant or rSLY protein (1µg/ml)-induced surface GPIIb/IIIa (CD41a) increase and fibrinogen binding to platelets in human blood was assessed by flow
cytometry (Methods Section). Representative histograms for the MFI of CD41a/fibrinogen binding are shown in (B, left panel). Unpaired two-tailed Student’s t-test was
used for (B) statistical analysis. Mann–Whitney U-test was used for (C) statistical analysis. (D) PRP was preincubated with eptifibatide (10µM) for 15 min prior to
addition of S. suis supernatant or SLY protein. Platelet aggregation was expressed as a final percentage of light transmission. Unpaired two-tailed Student’s t-test was
used for statistical analysis. ADP (20µM) was used as the positive control for platelet activation. THB and PBS were the negative controls for the culture supernatant
and proteins, respectively. Data in panels (A–D) are expressed as the mean ± SD of three independent experiments, with each experiment using blood from a
different donor. P < 0.05 is considered to be the threshold for statistical significance; ns, not significant; 05ZYH33, wild type strain; 1sly, isogenic mutant of sly; Sup,
supernatant; rSLY, recombinant SLY.
to dense granules, 05ZYH33 supernatant and rSLY, as well
as positive control ADP, increased the surface GPIIb/IIIa
(CD41a, Figure 2B). However, the GPIIb/IIIa (CD41a) level
stimulated by the supernatant from the 1sly group was
almost equal to that of the THB/PBS control. Moreover,
binding of the ligand of GPIIb/IIIa fibrinogen to the platelet
surface also increased significantly in the presence of either
05ZYH33 supernatant, rSLY, or ADP (positive control);
however, the level of fibrinogen upon platelets exposed to the
supernatant from 1sly was as low as those of the background
controls THB and PBS (Figure 2C). These results indicate
that SLY is the sole S. suis protein that activates human
platelets.
GPIIb/IIIa is the prominent adhesion receptor on platelets
by virtue of its role in mediating platelet aggregation (Zarbock
et al., 2007). Therefore, eptifibatide, a specific inhibitor of
fibrinogen binding to the GPIIb/IIIa receptor, was used to
explore the role of GPIIb/IIIa in the SLY-induced platelet
aggregation. Pre-incubation of platelets with eptifibatide
(10µM) significantly decreased the platelet aggregation
induced by the supernatant of 05ZYH33 or rSLY (Figure 2D).
Besides GPIIb/IIIa, P-selectin is another important adhesion
molecule that mediates neutrophil–platelet, platelet–platelet,
and monocyte–platelet interactions (Gottschalk et al., 1995).
Although SLY induced P-selectin release in α-granules (data
not shown), in contrast to eptifibatide, the platelet aggregation
induced by SLY remained unaffected by pretreatment with an
anti-P-selectin antibody (Figure S3).
SLY-Induced Platelet Activation and
Aggregation Depend on Pore Formation on
Platelets
CDCs can bind to membrane cholesterol to create large pores
(350–450 Å in diameter) and consequently lyse the target cells
(Rossjohn et al., 1997; Gilbert et al., 1999). Free cholesterol can
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inhibit pore formation by CDCs (Giddings et al., 2004; Xu et al.,
2010). To determine whether SLY-induced platelet aggregation
is caused by pore formation, the cholesterol inhibition assay
was used in this study. One µg/ml rSLY exhibited equal
hemolytic activity to the supernatant of 05ZYH33 used in
this study (Figure 3A). Substantial platelet aggregation occurred
when rSLY was 1µg/ml, whereas 0.1µg/ml rSLY with lowest
hemolytic activity did not (Figure 3B). Interestingly, cholesterol
(100µg/ml) that inhibited the hemolytic activity of rSLY (Bi
et al., 2015) abrogated platelet aggregation (Figures 3B). ADP
(20µM) and rSLY (10µg/ml) induced 93.9% platelet aggregation
without a lag time, whereas at a low dose of rSLY (1µg/ml),
there was an approximate 3-min lag time prior to massive
stimulation (Figure S4), possibly because of SLY (10µg/ml)-
induced platelet lysis leading to the highest light transmission.
As expected, cholesterol (100µg/ml) significantly inhibited rSLY
(1µg/ml)-induced increased surface GPIIb/IIIa (CD41a) and
fibrinogen binding (Figures 3C,D). Cholesterol subsequently
inhibited 05ZYH33 supernatant-induced platelet aggregation
(Figure 3E). These results suggest that SLY-induced platelet
activation and aggregation depend on pore formation on
platelets.
SLY-Induced Platelet Activation and
Aggregation Required Pore
Formation-Dependent Ca2+ Influx
A previous study reported that Staphylococcus aureus α-toxin
promotes assembly of the prothrombinase complex, and that this
process was dependent on Ca2+ but not on platelet lysis (Arvand
et al., 1990). However, α-toxin belongs to the small β-barrel
pore-forming group of toxins with different structures to other
CDCs (Meesters et al., 2009; Xu et al., 2010). The mechanisms
underlying SLY-induced Ca2+ influx were investigated in the
present study. In Ca2+-free HBSS, rSLY (1µg/ml) caused a mild
increase in the intracellular Ca2+ levels in platelets (data not
shown). In contrast, in HBSS containing 2mM Ca2+, 1µg/ml
of SLY increased platelet intracellular Ca2+ levels dramatically,
whereas 0.1µg per mL SLY and the non-hemolytic recombinant
mutant SLYP353V did not (Figure 4A). In addition, cholesterol
FIGURE 3 | SLY-induced platelet activation and aggregation dependent on pore formation on platelets. (A) The hemolytic activity of 05ZYH33 supernatant
and rSLY. Culture supernatants of S. suis 05ZYH33 and rSLY were tested the hemolytic activity as described by Materials and Methods. One hemolytic unit is defined
as the reciprocal of the suilysin titer, which was calculated as the highest dilution of the supernatant/rSLY which caused at least 50% hemolysis. (B) Dose response of
rSLY-induced platelet aggregation and the cholesterol inhibiting effect. (C,D) The cholesterol inhibiting effect of rSLY-induced surface GPIIb/IIIa (CD41a) increase and
fibrinogen binding to platelets in human blood were assessed by flow cytometry (Methods Section). A total of 1µg/ml of rSLY and 100µg/ml of cholesterol were used.
(E) The cholesterol (100µg/ml) effect on S. suis supernatant-induced platelet aggregation was detected using a platelet aggregometer. Unpaired two-tailed Student’s
t-test was used for (C) statistical analysis. Unpaired t-test with Welch’s correction was used for (B,D,E) statistical analysis. THB and PBS were the negative controls
for culture supernatant and proteins, respectively. Cholesterol was dissolved in ethanol. rSLY, recombinant SLY; Cho, cholesterol; 1+Cho, 1µg/ml of rSLY added to
cholesterol. Data in panels (A–E) are expressed as the mean ± SD of three independent experiments, with each experiment using blood from a different donor. P <
0.05 is considered to be the threshold for statistical significance; ns, not significant; 05ZYH33, wild type strain; 1sly, isogenic mutant of sly; Sup, supernatant.
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FIGURE 4 | Pore dependent Ca2+ influx by SLY triggers platelet activation and aggregation. (A) rSLY induces Ca2+ influx in human platelets. The purified
platelets marked with fluo-8 were resuspended in HBSS (with 2 mM Ca2+), and rSLY (1µg/ml), rSLY (0.1µg/ml), rSLYP353V (1µg/ml), cholesterol (10µg/ml), or other
control reagents were added. Ca2+ influx to platelets was detected using a Varioskan Flash Multiplate Reader. (B,C) The EGTA effect on rSLY-induced surface
GPIIb/IIIa (CD41a) increase and fibrinogen binding to platelets in human blood was assessed by flow cytometry (Methods Section). Human blood was preincubated
with EGTA (3 mM) for 10 min prior to addition of rSLY (1µg/ml). Unpaired two-tailed Student’s t-test was used for (B) statistical analysis. (D) The EGTA (3 mM) effect
on S. suis supernatant-induced platelet aggregation was detected using a platelet aggregometer (Methods Section). Unpaired t-test with Welch’s correction was used
for (C,D) statistical analysis. THB and PBS were the negative controls for culture supernatant and proteins, respectively. EGTA was dissolved in H2O. Data in panels
(A–D) are expressed as the mean ± SD of three independent experiments, with each experiment using blood from a different donor. P < 0.05 is considered to be the
threshold for statistical significance; ns, not significant; Cho, cholesterol; rSLY, recombinant SLY; rSLYP353V, recombinant non-hemolytic mutant of SLYP353V;
05ZYH33, wild type strain; 1sly, isogenic mutant of sly; Sup, supernatant.
(100µg/ml) strongly diminished rSLY-induced Ca2+ influx
(Figure 4A). These results indicate that rSLY-induced Ca2+
influx may depend on rSLY cytotoxicity.
Agonists that stimulate platelet aggregation (e.g., ADP and
platelet-activating factor, PAF) commonly cause platelets to
mobilize Ca2+ stores and take up extracellular Ca2+, thereby
increasing the concentration of cytosolic Ca2+ (Bird et al., 2004).
The roles of Ca2+ influx in platelet activation and aggregation
were studied further by using EGTA to chelate the extracellular
Ca2+. Blockage of Ca2+ influx by EGTA significantly reduced
rSLY-induced platelet surface GPIIb/IIIa (CD41a, Figure 4B)
and fibrinogen binding (Figure 4C). Consequently, EGTA also
inhibited SLY-induced platelet aggregation (Figure 4D). With
the ADP positive control, ADP-induced platelet aggregation was
also blocked by EGTA (Figure 4D). Taken together, these results
indicate that pore dependent Ca2+ influx plays essential roles in
platelet activation and aggregation induced by SLY.
Platelet Signaling in Response to SLY
PLC-β-IP3/DAG-MLCK (Gottschalk et al., 1995; Rebecchi and
Pentyala, 2000; Rhee, 2001) and Rho-ROCK-MLCK signaling
(Klages et al., 1999) are usually involved in platelet activation by
agonists such as ADP and PAF. Signaling by PLC-β-IP3/DAG-
MLCK is often accompanied by an increase in intracellular Ca2+
binding to calmodulin (Bird et al., 2004). The final signaling
events for the pathways described above involve phosphorylation
of MLC by MLCK and this leads to actin–myosin interactions,
the consequence of which is platelet degranulation (Gottschalk
et al., 1995).
To investigate the possible signaling involved in platelet
activation induced by SLY, specific inhibitors were used.
Both the MLCK-specific inhibitor ML-7 and ROCK-specific
inhibitor Y27632 had no effect on SLY or ADP-induced
platelet aggregation (Figure 5A). However, ML-7 had some
effects on the increased surface GPIIb/IIIa (CD41a) that from
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FIGURE 5 | Platelet signaling in response to SLY. (A,B) rSLY
(1µg/mL)-induced platelet aggregation in PRP pretreated with or without
MLCK inhibitor ML-7 (100µM), ROCK inhibitor Y27632 (100 µM), and PLC-β
inhibitor U73122 (20µM). Unpaired t-test with Welch’s correction was used for
(A,B) statistical analyses. (C) The effects of ML-7 (100µM) and eptifibatide
(10µM) on rSLY-induced surface GPIIb/IIIa (CD41a) increase. Unpaired
two-tailed Student’s t-test was used for statistical analysis. PBS is the negative
control for rSLY protein. ML-7, Y27632, and eptifibatide were dissolved in
H2O. U73122 was dissolved in ethanol. Data in panels (A–C) are given as the
mean ± SD of 3–8 independent experiments from different blood donors.
P < 0.05 is considered to be the threshold for statistical significance; ns, not
significant.
α-granules release (Figure 5C). In combination with the results
shown in Figure 2D, these results suggest that SLY-induced
aggregation seems to depend on the high-affinity of fibrinogen for
activated GPIIb/IIIa (CD41a), rather than increase the number of
GPIIb/IIIa (∼30%) resulting from α-granule release induced by
SLY (Figure 3C).
The PLC-β-specific inhibitor U73122 significantly decreased
ADP-induced platelet aggregation, but had no effect on
SLY-induced platelet aggregation (Figure 5B). Interestingly,
these data suggest that SLY-induced platelet aggregation did
not occur via PLC-β-IP3/DAG-MLCK or Rho-ROCK-MLCK
signaling.
SLY activates human platelets resulting in an “inside-out”
signaling leading to integrin GPIIb/IIIa (CD41a) activation and
this promotes binding to the fibrinogen present in the plasma
(Figure 2B). The ligand-occupied GPIIb/IIIa (CD41a) in turn
usually reinforces activation of “outside-in” signaling leading to
secretion of α-granules. However, eptifibatide had no effect on
GPIIb/IIIa (CD41a) (Figure 5C); this probably results from the
limited amounts of GPIIb/IIIa (∼30%) in the membranes of
α-granule (Phillips et al., 1988; Bennett, 2005).
Intravascular Thrombosis and Associated
Liver Injury Caused by SLY in Mice
In our early study, S. suis 05ZYH33 induced higher mean
platelet volume and lower platelets counts in mice blood than
S. suis 1sly, suggesting that SLY induced platelet activation
in mice-infecting model (Zhang et al., 2016). Moreover, the
contribution of SLY to platelet aggregation in this study led
us to further examine the role of simultaneous targeting of
platelets in relation to pathology in vivo. Female BALB/c mice
(6–8 weeks old) were challenged with 05ZYH33 or mutant 1sly
bacteria, through the caudal vein. Pathological changes in the
mice were observed by hematoxylin and eosin stained tissue
sections at 48 h post-inoculation. Vessels within the liver tissues
infected by 05ZYH33 showed a remarkable level of intravascular
thrombi (Figures 6A-b,B-b). Moreover, coagulative necrosis
(Figures 6A-c,B-c) and leukocyte infiltration (Figures 6A-d,B-d)
surrounding the vein vessel (Figure 6A-a) or artery vessel
(Figure 6B-a) were apparent. However, intravascular thrombi
with surrounding coagulative necrosis and leukocyte infiltration
were not observed in the vessels of live tissues infected by 1sly
(Figure 6C) or in the PBS control group (Figure 6D). Part II
panels represent the enlarged images of the white boxes shown
in part I panels of Figures 6A–D.
Other CDCs Promote the Platelet
Aggregation Required for Pore Dependent
Calcium Influx
PLY and SLO are important pathogen toxins of S. pneumoniae
and S. pyogenes, respectively. They are toxins from group I,
which comprises typical CDCs with high affinity for cholesterol
and high structural similarity to SLY (Giddings et al., 2004).
Therefore, PLY and SLO possibly share similar functional
characteristics to SLY. Interestingly, cholesterol completely
inhibits the cytotoxicity of 0.8µg/ml PLY and 1.5µg/ml SLO
(Figures 7A,B), and also abrogates their platelet aggregation
inducing abilities (Figure 7C). Moreover, EGTA has inhibiting
effects on the platelet aggregation induced by PLY and
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FIGURE 6 | SLY contributes to the intravascular thrombosis and its associated liver injury caused by S. suis. Female BALB/c mice (6–8 weeks old) were
challenged with (A,B) 05ZYH33; (C) mutant 1sly (∼1×108 CFU); (D) PBS control through the caudal vein. Pathological changes were observed by hematoxylin and
eosin pathological staining of tissue sections at 48 h post-inoculation. Panels numbered II are the enlarged images from the white boxes in panels numbered I. a, b, c,
and d in the panels represent blood vessels, intravascular thrombosis, coagulative necrosis, and leukocyte infiltration, respectively.
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FIGURE 7 | rPLY and rSLO induce platelet aggregation via pore dependent calcium influx. The cytotoxicity of rPLY (A) and rSLO (B) against platelets and the
cholesterol inhibiting effect were assessed by an LDH assay (Methods Section). (C) The cholesterol (100µg/mL) effect on rPLY (0.8µg/mL)- and rSLO
(1.5µg/mL)-induced platelet aggregation. (D) The EGTA (3 mM) effect on rPLY (0.8µg/mL)- and rSLO (1.5µg/mL)-induced PNA formation. PBS acted as the negative
control for the recombinant proteins. Cholesterol and EGTA were dissolved in ethanol and H2O, respectively. Unpaired t-test with Welch’s correction was used for
(A,B,D) statistical analyses. Unpaired two-tailed Student’s t-test was used for (C) statistical analysis. Data in panels (A–D) are given as the mean ± SD of three
independent experiments, with each experiment using blood from a different donor. P < 0.05 is considered to be the threshold for statistical significance; ns, not
significant; rPLY, recombinant pneumolysin; rSLO, recombinant streptolysin O; Cho, cholesterol; 0.8+Cho, 0.8µg/mL of rPLY added to cholesterol; 1.5+Cho,
1.5µg/mL of rSLO added to cholesterol.
SLO (Figure 7D), although the difference was not statistically
significant in the SLO group. It is possible that CDC-mediated
platelet aggregation is a common mechanism used by a wide
range of bacteria, and is triggered by pore dependent calcium
influx.
DISCUSSION
We have identified the cytolysin SLY is the main stimulus
required for human platelet activation in S. suis 05ZYH33, which
is a sequenced strain belonging to sequence type 7 (ST-7) strains
that caused the 2005 S. suis outbreak and STSS in China (Ye
et al., 2009). Our systematic analysis of SLY found that it induces
platelet activation and aggregation triggered by pore dependent
Ca2+ influx.
Different from S. aureus, S. pyogenes, and S. pneumoniae,
SLY was found to be the sole factor inducing human platelet
activation and aggregation. For example, the fibrinogen-binding
proteins, ClfA, ClfB, and SdrE of S. aureus can all interact with
GPIIb/IIIa, generating an outside-in signal to trigger platelet
aggregation (O’brien et al., 2002; Liu et al., 2007). S. suis is
an emerging human pathogen that causes STSS. ST-7 strains
caused the outbreak in humans in China in 2005 and were more
toxic to human peripheral blood mononuclear cells than ST-1
strains (mainly referring to the European virulent strains) (Ye
et al., 2006). In particular, we have previously shown that the
ST-7 strains produce more SLY protein than the non-epidemic
strains, and this contributes to invasive infections (He et al.,
2014). Additionally, similar to STSS patients infected by S. suis,
05ZYH33 induced intravascular thrombosis and associated-liver
injury in our mouse infection model (Figure 6). Therefore, SLY
may be a potential therapeutic target for preventing S. suis-
mediated platelet activation, thrombocytopenia related DIC, and
purpura gangrenosa.
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Although it has been reported that there are 20 types of
bacterial cytolysin belonging to Group I CDCs with high affinity
to cholesterol (Tabata et al., 2014), there is scant evidence
showing associations existing betweenGroup I CDCs and platelet
activation. Ohkuni et al. has reported that recombinant SLY,
PLY, and Sm-hPAF were stimuli capable of inducing platelet
aggregation (Ohkuni et al., 2012). However, the mechanisms
underlying how these bacterial toxins induce platelet activation
are not clearly understood. In a comprehensive review, Cox et al.
proposed that pore-forming toxins activate platelets in a manner
similar to α-toxin (Cox et al., 2011), but the data in the articles
cited in this review did not clearly support this viewpoint. Our
current study presents direct evidence showing that SLY induced
a pore dependent Ca2+ influx in platelets, which was required for
SLY-induced platelet aggregation; the other two CDCs, PLY, and
SLO, also induced platelet aggregation in a similar manner.
The present study also found that SLY-induced platelet
GPIIb/IIIa (CD41a) activation was Ca2+ influx dependent,
suggesting that stimulation of this adhesion factor appears
to be downstream of SLY-induced Ca2+ influx. Contrastingly,
MLCK may not be involved in platelet aggregation because
ML-7 failed to suppress SLY-induced platelet aggregation
although it inhibited GPIIb/IIIa (CD41a) release in α-granules
(Figures 5A,C). SLY-induced Ca2+ influx may directly activate
“inside-out” signaling to enhance the affinity of GPIIb/IIIa to
fibrinogen, which subsequently induces platelet aggregation.
We also found that the PLC-β inhibitor U73122 dramatically
decreased ADP-induced platelet aggregation but had no impact
on SLY-induced platelet aggregation. The data imply that the
signaling events involved in SLY-induced platelet activation
may differ from typical platelet agonists such as ADP and
thromboxane A2 (TXA2) because these are dependent on PLC-
β associated signaling (Zarbock et al., 2007). Furthermore, Born
aggregometry revealed that SLY-induced platelet aggregation
showed a 3-min lag time prior to massive aggregation occurring
(Figure S4). In contrast, most platelet agonists such as ADP cause
rapid activation (Cox et al., 2011). The differential dynamics
for SLY-induced platelet aggregation and ADP-induced platelet
aggregation also suggest that distinct signaling might be induced
by SLY.
Overall, we found that SLY, which was secreted by S. suis
05ZYH33 at the stationary growth phase, stimulated platelet
activation and aggregation. This stimulation required SLY-
induced Ca2+ influx and subsequent “inside-out” signaling to
activate GPIIb/IIIa (CD41a) (as proposed in Figure 8).Moreover,
PLY, SLO, and SLY, which are all Group I CDCs, seem to share
similar mechanisms for inducing platelet aggregation.We foresee
that this similar mode of activation identifies Group I CDCs
as potential therapeutic targets for preventing bacterial-induced
platelet activation and thrombotic-related disorders.
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Figure S1 | The purity of human platelets in PRP. (A) Leukocytes in human
blood were analyzed by flow cytometry as forward- and side-scatter. (B) PRP was
analyzed by flow cytometry as forward- and side-scatter. (C) The percent of
CD41a positive cells in panel (B) was shown as representative histograms. The
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platelets in PRP were detected by flow cytometry analysis using FITC conjugated
anti-CD41a (clone HIP8) antibody.
Figure S2 | The activity of S. suis-induced platelet aggregation. (A) The
culture supernatant and the washed bacteria cells of S. suis were added to PRP in
a stirred cuvette. Platelet aggregation was expressed as a final percentage of light
transmission detected by Platelet Aggregometer se-2000. ADP (20µM) and THB
were used as the positive controls and negative controls, respectively. Data are
expressed as the mean ± SD of three independent experiments, with each
experiment using blood from a different donor. (B) The platelet aggregation curves
shown in panel B are from one representative experiment of three independent
experiments. S. suis 4 (SLY+, 89K+) isolated from human patient in China (2005);
S. suis 4005 (SLY+, 89K−) and s735 (SLY+, 89K−) isolated from diseased piglets
in Netherlands; S. suis 1940 (SLY+, 89K−) isolated from diseased piglets in China
(1980); Sup, supernatant; SLY, suilysin; 89K−, 89 kb pathogenicity island.
Figure S3 | S. suis supernatant and rSLY-induced platelet aggregation in
PRP was assessed in the presence of 15µL anti-CD62P blocking antibody
or an isotype-matched control antibody (BD Bioscience). Unpaired
two-tailed Student’s t-test was used for statistical analysis. Data in are expressed
as the mean ± SD for three independent experiments, with each experiment using
blood from a different donor. P < 0.05 is considered as the threshold for
significance; ns, no significance; 05ZYH33, wild type strain; 1sly, The isogenic
mutants of sly; Sup, supernatant.
Figure S4 | Dose response of rSLY-induced platelet aggregation. Serial
concentrations of SLY were added to platelet-rich plasma (PRP) in a stirred
cuvette. Platelet aggregation was expressed as a final percentage of light
transmission.
Table S1 | Bacterial strains and plasmids used in this study.
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